ALLO

Allogene Therapeutics, Inc.

NASDAQHealthcareBiotechnologyUS

USD2.22

+0.09 (+4.23%)

Rating:C-

Company Profile

CEO

David D. Chang

IPO Date

2018-10-11

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

Market Metrics

Open

$2.15

Prev. Close

$2.13

Day Low

$2.13

Day High

$2.24

52W Low

$0.98

52W High

$4.46

Market Cap

$0.54B

Volume

14.64M

News SentimentBullish

Articles

Avg Positive

40.5%

Avg Negative

2.3%

Avg Neutral

57.0%

News Feed

Allogene Therapeutics to Report Second Quarter Financial Results on August 4, 2021

GlobeNewsWire·7/27/2021·↓ negative

Allogene (ALLO) Multiple Myeloma Candidate Gets Fast Track Tag

Zacks Investment Research·7/1/2021·↑ positive

Allogene Therapeutics Granted FDA Fast Track Designation for ALLO-605, the First TurboCAR™ T Cell Therapy, for the Treatment of Relapsed/Refractory Multiple Myeloma